In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The End of the Pharmaceutical Blockbuster

Executive Summary

The 90's have seen a pharmaceutical industry dominated by "mega blockbusters." But according to a study published by the Boston Consulting Group, the days of the blockbuster as a vehicle for sustainable success are limited. Rather, drug companies will gradually move away from broad-scale products with lower efficacy toward targeted products that offer greater efficacy to smaller patient populations. The shift away from blockbusters will be driven by pharmacogenomics but also by "consumer-centric care."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV000832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel